Axsome Thera (AXSM)

$235.26 +6.98 (3.06%)
Market Cap 11.75B
Revenue (ttm) 638.50M
Net Income (ttm) -183.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28.69%
Debt to Equity Ratio 2.16
Volume 482,700
Avg Vol 950,990
Day's Range N/A - N/A
Shares Out 51.46M
Stochastic %K 38%
Beta 0.60
Analysts Strong Sell
Price Target $273.24

Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptak...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 332 3241
Fax: 212 320 0245
Address:
One World Trade Center, 29th Floor, New York, United States
Mike826_1999
Mike826_1999 Jul. 15 at 1:47 AM
$AXSM Ketamine and Auvelity, similar but different. https://www.youtube.com/watch?v=O-wyMpCOom0
0 · Reply
Mike826_1999
Mike826_1999 Jul. 15 at 12:57 AM
$AXSM Antecip Bioventures, HT's company that owns the intellectual property behind Auvelity, was issued another U.S. patent today, Patent No. 12,678,506. It is not an earth shattering development or a new indication, but it does provide another layer of intellectual property protection for Auvelity. This patent focuses on formulation technology designed to improve the stability of bupropion by using cysteine. It joins a long and growing list of patents protecting Auvelity. This is part of a common strategy of building a broad patent estate, making it increasingly difficult for generic manufacturers to design around the company's IP. While this patent alone is unlikely to move the stock, each additional patent further strengthens Axsome's competitive position and helps protect one of its most valuable assets.
0 · Reply
Vakeshka
Vakeshka Jul. 15 at 12:43 AM
$AXSM new Smart Money buys in. 14 July, 2026 "Hillsdale Investment Management Inc. purchased a new position in shares of Axsome Therapeutics, Inc. during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 53,363 shares of the company's stock, valued at approximately $9,019,000. Hillsdale Investment Management Inc. owned approximately 0.10% of Axsome Therapeutics as of its most recent SEC filing."
0 · Reply
Mike826_1999
Mike826_1999 Jul. 15 at 12:10 AM
$AXSM AXS-05 Smoking Cessation - New Trademark Application
1 · Reply
Georgejj
Georgejj Jul. 14 at 11:25 PM
$AXSM Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10, 2026 https://finance.yahoo.com/healthcare/articles/axsome-therapeutics-report-second-quarter-110000110.html Good luck and GOD bless,
0 · Reply
Bobear12
Bobear12 Jul. 14 at 10:07 PM
$AXSM Now. $GALT Jelly, a marriage between MDGL and GALT would be a marriage made in heaven for all Liver disease patients. Bo-picks-MDGL
0 · Reply
LuigiV_
LuigiV_ Jul. 14 at 8:16 PM
$ATI $AFRM $STT $AXSM iq
1 · Reply
Bobear12
Bobear12 Jul. 14 at 7:05 PM
$AXSM News: MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation. A Stocktwits user opined that Madrigal can buy smaller rival pharma player Galectin Therapeutics to expand its portfolio. Galectin is developing belapectin for MASH patients with cirrhosis and portal hypertension. Another user said that big pharma player Eli Lilly and Co might choose between either Madrigal or Galectin to expand its own liver disease pipeline.
0 · Reply
Kenzo71
Kenzo71 Jul. 14 at 6:42 PM
$AXSM I apologize if this question has already been asked and answered, but isn’t the Company expecting a response from the FDA this week regarding whether their PDUFA filing was accepted for the use of AXS-12 for cataplexy in patients with narcolepsy?
5 · Reply
Bobear12
Bobear12 Jul. 14 at 3:51 PM
$AXSM $GALT Jelly $5 calls for $.40c on 7/17/26. What do you think? Up+17% 2day. Bo
0 · Reply
Latest News on AXSM
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

Jul 14, 2026, 7:00 AM EDT - 21 hours ago

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

Axsome Therapeutics price target raised to $304 from $302 at RBC Capital

2026-07-07T11:30:22.000Z - 7 days ago

Axsome Therapeutics price target raised to $304 from $302 at RBC Capital

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

Jul 7, 2026, 7:00 AM EDT - 7 days ago

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

Why Axsome Stock Has Doubled In Nine Months

Jul 1, 2026, 12:10 PM EDT - 13 days ago

Why Axsome Stock Has Doubled In Nine Months

Axsome Therapeutics doses first patient in FOCUS-3 trial

2026-06-26T11:11:10.000Z - 18 days ago

Axsome Therapeutics doses first patient in FOCUS-3 trial

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

Jun 26, 2026, 7:00 AM EDT - 18 days ago

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month

Jun 18, 2026, 7:00 AM EDT - 26 days ago

Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month

CNS

Axsome Therapeutics price target raised to $300 from $275 at TD Cowen

2026-06-17T12:26:14.000Z - 27 days ago

Axsome Therapeutics price target raised to $300 from $275 at TD Cowen

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026

Jun 15, 2026, 7:00 AM EDT - 4 weeks ago

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026

Axsome Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 3:20 PM EDT - 5 weeks ago

Axsome Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Axsome Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 10:30 AM EDT - 5 weeks ago

Axsome Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

Jun 4, 2026, 7:00 AM EDT - 5 weeks ago

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

Axsome Therapeutics Transcript: 46th Annual William Blair Growth Stock Conference

Jun 3, 2026, 3:40 PM EDT - 5 weeks ago

Axsome Therapeutics Transcript: 46th Annual William Blair Growth Stock Conference

Axsome Therapeutics announces settlement resolving Sunosi patent litigation

2026-06-03T12:28:19.000Z - 5 weeks ago

Axsome Therapeutics announces settlement resolving Sunosi patent litigation

Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

Jun 3, 2026, 7:00 AM EDT - 5 weeks ago

Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

Jun 1, 2026, 7:00 AM EDT - 6 weeks ago

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

Axsome Therapeutics to Participate in Upcoming Investor Conferences

May 27, 2026, 7:00 AM EDT - 6 weeks ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

May 26, 2026, 7:00 AM EDT - 7 weeks ago

Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

Axsome Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 1:35 PM EDT - 2 months ago

Axsome Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

Axsome Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 11:40 AM EDT - 2 months ago

Axsome Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

Axsome Therapeutics Recognizes Mental Health Month

May 7, 2026, 7:00 AM EDT - 2 months ago

Axsome Therapeutics Recognizes Mental Health Month

Axsome Therapeutics price target lowered to $280 from $281 at Deutsche Bank

2026-05-05T13:03:09.000Z - 2 months ago

Axsome Therapeutics price target lowered to $280 from $281 at Deutsche Bank

Axsome Therapeutics price target raised to $267 from $255 at Needham

2026-05-05T12:50:34.000Z - 2 months ago

Axsome Therapeutics price target raised to $267 from $255 at Needham

Axsome Therapeutics price target raised to $242 from $217 at Morgan Stanley

2026-05-05T12:47:49.000Z - 2 months ago

Axsome Therapeutics price target raised to $242 from $217 at Morgan Stanley

Axsome Therapeutics price target raised to $302 from $242 at RBC Capital

2026-05-05T12:30:30.000Z - 2 months ago

Axsome Therapeutics price target raised to $302 from $242 at RBC Capital

Axsome Therapeutics price target raised to $310 from $228 at Mizuho

2026-05-05T12:05:49.000Z - 2 months ago

Axsome Therapeutics price target raised to $310 from $228 at Mizuho

Axsome Therapeutics price target raised to $246 from $241 at Baird

2026-05-05T10:33:20.000Z - 2 months ago

Axsome Therapeutics price target raised to $246 from $241 at Baird

Axsome Therapeutics price target raised to $290 from $270 at H.C. Wainwright

2026-05-05T10:10:17.000Z - 2 months ago

Axsome Therapeutics price target raised to $290 from $270 at H.C. Wainwright

Axsome Therapeutics price target raised to $276 from $239 at BofA

2026-05-05T09:30:26.000Z - 2 months ago

Axsome Therapeutics price target raised to $276 from $239 at BofA

Axsome Therapeutics price target raised to $280 from $250 at Oppenheimer

2026-05-04T19:25:22.000Z - 2 months ago

Axsome Therapeutics price target raised to $280 from $250 at Oppenheimer

Axsome Therapeutics management to meet with Needham

2026-05-04T19:21:02.000Z - 2 months ago

Axsome Therapeutics management to meet with Needham

Axsome Therapeutics management to meet with Piper Sandler

2026-05-04T19:20:53.000Z - 2 months ago

Axsome Therapeutics management to meet with Piper Sandler

Axsome Therapeutics price target raised to $260 from $245 at Guggenheim

2026-05-04T17:20:15.000Z - 2 months ago

Axsome Therapeutics price target raised to $260 from $245 at Guggenheim

Axsome Therapeutics price target raised to $258 from $223 at Piper Sandler

2026-05-04T16:35:10.000Z - 2 months ago

Axsome Therapeutics price target raised to $258 from $223 at Piper Sandler

Axsome Therapeutics price target raised to $272 from $234 at Cantor Fitzgerald

2026-05-04T16:02:51.000Z - 2 months ago

Axsome Therapeutics price target raised to $272 from $234 at Cantor Fitzgerald

Axsome Therapeutics price target raised to $275 from $245 at Jefferies

2026-05-04T15:15:24.000Z - 2 months ago

Axsome Therapeutics price target raised to $275 from $245 at Jefferies

Axsome Therapeutics Earnings Call Transcript: Q1 2026

May 4, 2026, 8:00 AM EDT - 2 months ago

Axsome Therapeutics Earnings Call Transcript: Q1 2026

Axsome Therapeutics Earnings release: Q1 2026

May 4, 2026, 8:00 AM EDT - 2 months ago

Axsome Therapeutics Earnings release: Q1 2026

Axsome Therapeutics Slides: Q1 2026

May 4, 2026, 8:00 AM EDT - 2 months ago

Axsome Therapeutics Slides: Q1 2026

Axsome Therapeutics Quarterly report: Q1 2026

May 4, 2026, 8:00 AM EDT - 2 months ago

Axsome Therapeutics Quarterly report: Q1 2026

Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 4, 2026, 7:00 AM EDT - 2 months ago

Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Axsome Therapeutics Transcript: FDA announcement

May 1, 2026, 8:00 AM EDT - 2 months ago

Axsome Therapeutics Transcript: FDA announcement

Axsome Therapeutics Press release: FDA announcement

May 1, 2026, 8:00 AM EDT - 2 months ago

Axsome Therapeutics Press release: FDA announcement

Axsome Therapeutics Slides: FDA announcement

May 1, 2026, 8:00 AM EDT - 2 months ago

Axsome Therapeutics Slides: FDA announcement

Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader

May 1, 2026, 7:15 AM EDT - 2 months ago

Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader

US FDA approves Axsome's drug for Alzheimer's-related agitation

Apr 30, 2026, 2:10 PM EDT - 2 months ago

US FDA approves Axsome's drug for Alzheimer's-related agitation

Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease

Apr 30, 2026, 2:06 PM EDT - 2 months ago

Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease

Axsome Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Axsome Therapeutics Proxy statement: Proxy filing

Axsome Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Axsome Therapeutics Proxy statement: Proxy filing

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

Apr 8, 2026, 7:00 AM EDT - 3 months ago

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

Axsome Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 4:00 PM EDT - 4 months ago

Axsome Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Axsome Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:20 PM EDT - 4 months ago

Axsome Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Axsome Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 3:10 PM EST - 4 months ago

Axsome Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Axsome Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 2:00 PM EST - 4 months ago

Axsome Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Axsome Therapeutics Earnings Call Transcript: Q4 2025

Feb 23, 2026, 8:00 AM EST - 5 months ago

Axsome Therapeutics Earnings Call Transcript: Q4 2025

Axsome Therapeutics Annual report: Q4 2025

Feb 23, 2026, 8:00 AM EST - 5 months ago

Axsome Therapeutics Annual report: Q4 2025

Axsome Therapeutics Earnings release: Q4 2025

Feb 23, 2026, 8:00 AM EST - 5 months ago

Axsome Therapeutics Earnings release: Q4 2025

Axsome Therapeutics Slides: Q4 2025

Feb 23, 2026, 8:00 AM EST - 5 months ago

Axsome Therapeutics Slides: Q4 2025

Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 7:00 AM EST - 5 months ago

Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

Feb 17, 2026, 7:00 AM EST - 5 months ago

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

Jan 27, 2026, 7:00 AM EST - 6 months ago

Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

Jan 12, 2026, 7:00 AM EST - 6 months ago

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission

Dec 31, 2025, 6:55 AM EST - 6 months ago

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission

Axsome Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 4:00 PM EST - 7 months ago

Axsome Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Axsome Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 11:00 AM EST - 8 months ago

Axsome Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Nov 6, 2025, 7:00 AM EST - 8 months ago

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

Nov 6, 2025, 7:00 AM EST - 8 months ago

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

FBIO

Axsome Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:00 AM EST - 9 months ago

Axsome Therapeutics Earnings Call Transcript: Q3 2025

Axsome Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 8:00 AM EST - 9 months ago

Axsome Therapeutics Quarterly report: Q3 2025

Axsome Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 8:00 AM EST - 9 months ago

Axsome Therapeutics Earnings release: Q3 2025

Axsome Therapeutics Slides: Q3 2025

Nov 3, 2025, 8:00 AM EST - 9 months ago

Axsome Therapeutics Slides: Q3 2025

Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 24, 2025, 11:20 AM EDT - 9 months ago

Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community

Oct 9, 2025, 7:00 AM EDT - 9 months ago

Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

Oct 7, 2025, 7:00 AM EDT - 10 months ago

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

Axsome Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 17, 2025, 8:40 AM EDT - 10 months ago

Axsome Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

Sep 17, 2025, 7:00 AM EDT - 10 months ago

Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

Axsome Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 2:35 PM EDT - 11 months ago

Axsome Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Axsome Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 1:00 PM EDT - 11 months ago

Axsome Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Axsome Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 3:45 PM EDT - 11 months ago

Axsome Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Axsome Therapeutics Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Axsome Therapeutics Earnings Call Transcript: Q2 2025

Axsome Therapeutics Quarterly report: Q2 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Axsome Therapeutics Quarterly report: Q2 2025

Axsome Therapeutics Earnings release: Q2 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Axsome Therapeutics Earnings release: Q2 2025

Axsome Therapeutics Slides: Q2 2025

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Axsome Therapeutics Slides: Q2 2025

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Axsome Therapeutics Transcript: R&D Day 2025

Jul 21, 2025, 11:00 AM EDT - 1 year ago

Axsome Therapeutics Transcript: R&D Day 2025

Axsome Therapeutics Slides: FY 2025

Jul 21, 2025, 11:00 AM EDT - 1 year ago

Axsome Therapeutics Slides: FY 2025

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Jul 21, 2025, 7:30 AM EDT - 1 year ago

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

Jul 9, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

Jul 7, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

Jun 20, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

Jun 11, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

Axsome Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 2:40 PM EDT - 1 year ago

Axsome Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Axsome Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 2:35 PM EDT - 1 year ago

Axsome Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Axsome Therapeutics Transcript: 45th Annual William Blair Growth Stock Conference

Jun 3, 2025, 11:40 AM EDT - 1 year ago

Axsome Therapeutics Transcript: 45th Annual William Blair Growth Stock Conference

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

May 27, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

Axsome Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 3:05 PM EDT - 1 year ago

Axsome Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

Axsome Therapeutics Transcript: Bank of America 2025 Healthcare Conference

May 13, 2025, 6:00 PM EDT - 1 year ago

Axsome Therapeutics Transcript: Bank of America 2025 Healthcare Conference

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

May 13, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

Axsome Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 1:30 PM EDT - 1 year ago

Axsome Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

Axsome Therapeutics Earnings Call Transcript: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Axsome Therapeutics Earnings Call Transcript: Q1 2025

Axsome Therapeutics Quarterly report: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Axsome Therapeutics Quarterly report: Q1 2025

Axsome Therapeutics Earnings release: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Axsome Therapeutics Earnings release: Q1 2025

Axsome Therapeutics Slides: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Axsome Therapeutics Slides: Q1 2025

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

May 1, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

Axsome Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Axsome Therapeutics Proxy statement: Proxy Filing

Axsome Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Axsome Therapeutics Proxy statement: Proxy Filing

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

Apr 8, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

Apr 4, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

Axsome's depression treatment fails to meet main goal of late-stage study

Apr 1, 2025, 7:18 AM EDT - 1 year ago

Axsome's depression treatment fails to meet main goal of late-stage study

Axsome Therapeutics' ADHD drug meets main goal in late-stage study

Mar 25, 2025, 7:13 AM EDT - 1 year ago

Axsome Therapeutics' ADHD drug meets main goal in late-stage study

Axsome Therapeutics Transcript: Leerink Global Biopharma Conference 2025

Mar 12, 2025, 10:40 AM EDT - 1 year ago

Axsome Therapeutics Transcript: Leerink Global Biopharma Conference 2025

Axsome Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 9:50 AM EST - 1 year ago

Axsome Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Axsome Therapeutics Earnings Call Transcript: Q4 2024

Feb 18, 2025, 8:00 AM EST - 1 year ago

Axsome Therapeutics Earnings Call Transcript: Q4 2024

Axsome Therapeutics Annual report: Q4 2024

Feb 18, 2025, 8:00 AM EST - 1 year ago

Axsome Therapeutics Annual report: Q4 2024

Axsome Therapeutics Earnings release: Q4 2024

Feb 18, 2025, 8:00 AM EST - 1 year ago

Axsome Therapeutics Earnings release: Q4 2024

Axsome Therapeutics Slides: Q4 2024

Feb 18, 2025, 8:00 AM EST - 1 year ago

Axsome Therapeutics Slides: Q4 2024

Axsome Therapeutics Transcript: FDA Announcement

Jan 31, 2025, 8:00 AM EST - 1 year ago

Axsome Therapeutics Transcript: FDA Announcement

Axsome Therapeutics Press release: FDA Announcement

Jan 31, 2025, 8:00 AM EST - 1 year ago

Axsome Therapeutics Press release: FDA Announcement

Axsome Therapeutics Slides: FDA Announcement

Jan 31, 2025, 8:00 AM EST - 1 year ago

Axsome Therapeutics Slides: FDA Announcement

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

Jan 31, 2025, 7:00 AM EST - 1 year ago

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

US FDA approves Axsome Therapeutics' migraine drug

Jan 30, 2025, 3:55 PM EST - 1 year ago

US FDA approves Axsome Therapeutics' migraine drug

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

Jan 30, 2025, 3:45 PM EST - 1 year ago

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

Axsome Therapeutics Transcript: Study Result

Dec 30, 2024, 8:00 AM EST - 1 year ago

Axsome Therapeutics Transcript: Study Result

Axsome Therapeutics Press release: Study Result

Dec 30, 2024, 8:00 AM EST - 1 year ago

Axsome Therapeutics Press release: Study Result

Axsome Therapeutics Slides: Study Result

Dec 30, 2024, 8:00 AM EST - 1 year ago

Axsome Therapeutics Slides: Study Result

Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study

Dec 30, 2024, 7:15 AM EST - 1 year ago

Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation

Dec 30, 2024, 7:00 AM EST - 1 year ago

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation

Axsome Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Axsome Therapeutics Earnings Call Transcript: Q3 2024

Axsome Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Axsome Therapeutics Quarterly report: Q3 2024

Axsome Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Axsome Therapeutics Earnings release: Q3 2024

Axsome Therapeutics Slides: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Axsome Therapeutics Slides: Q3 2024

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

Mike826_1999
Mike826_1999 Jul. 15 at 1:47 AM
$AXSM Ketamine and Auvelity, similar but different. https://www.youtube.com/watch?v=O-wyMpCOom0
0 · Reply
Mike826_1999
Mike826_1999 Jul. 15 at 12:57 AM
$AXSM Antecip Bioventures, HT's company that owns the intellectual property behind Auvelity, was issued another U.S. patent today, Patent No. 12,678,506. It is not an earth shattering development or a new indication, but it does provide another layer of intellectual property protection for Auvelity. This patent focuses on formulation technology designed to improve the stability of bupropion by using cysteine. It joins a long and growing list of patents protecting Auvelity. This is part of a common strategy of building a broad patent estate, making it increasingly difficult for generic manufacturers to design around the company's IP. While this patent alone is unlikely to move the stock, each additional patent further strengthens Axsome's competitive position and helps protect one of its most valuable assets.
0 · Reply
Vakeshka
Vakeshka Jul. 15 at 12:43 AM
$AXSM new Smart Money buys in. 14 July, 2026 "Hillsdale Investment Management Inc. purchased a new position in shares of Axsome Therapeutics, Inc. during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 53,363 shares of the company's stock, valued at approximately $9,019,000. Hillsdale Investment Management Inc. owned approximately 0.10% of Axsome Therapeutics as of its most recent SEC filing."
0 · Reply
Mike826_1999
Mike826_1999 Jul. 15 at 12:10 AM
$AXSM AXS-05 Smoking Cessation - New Trademark Application
1 · Reply
Georgejj
Georgejj Jul. 14 at 11:25 PM
$AXSM Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10, 2026 https://finance.yahoo.com/healthcare/articles/axsome-therapeutics-report-second-quarter-110000110.html Good luck and GOD bless,
0 · Reply
Bobear12
Bobear12 Jul. 14 at 10:07 PM
$AXSM Now. $GALT Jelly, a marriage between MDGL and GALT would be a marriage made in heaven for all Liver disease patients. Bo-picks-MDGL
0 · Reply
LuigiV_
LuigiV_ Jul. 14 at 8:16 PM
$ATI $AFRM $STT $AXSM iq
1 · Reply
Bobear12
Bobear12 Jul. 14 at 7:05 PM
$AXSM News: MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation. A Stocktwits user opined that Madrigal can buy smaller rival pharma player Galectin Therapeutics to expand its portfolio. Galectin is developing belapectin for MASH patients with cirrhosis and portal hypertension. Another user said that big pharma player Eli Lilly and Co might choose between either Madrigal or Galectin to expand its own liver disease pipeline.
0 · Reply
Kenzo71
Kenzo71 Jul. 14 at 6:42 PM
$AXSM I apologize if this question has already been asked and answered, but isn’t the Company expecting a response from the FDA this week regarding whether their PDUFA filing was accepted for the use of AXS-12 for cataplexy in patients with narcolepsy?
5 · Reply
Bobear12
Bobear12 Jul. 14 at 3:51 PM
$AXSM $GALT Jelly $5 calls for $.40c on 7/17/26. What do you think? Up+17% 2day. Bo
0 · Reply
jlfromli
jlfromli Jul. 14 at 3:45 PM
$AXSM It’s not Going to Zero! Thank Goodness.
1 · Reply
Bobear12
Bobear12 Jul. 14 at 2:17 PM
$AXSM it’s wild over at GALT. The next AXSM. Come join us. Bo
0 · Reply
quickaspeter
quickaspeter Jul. 14 at 1:22 PM
$AXSM …announced it will report its financial results for the Q2 of 2026 on Monday, August 10, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.
0 · Reply
Kenzo71
Kenzo71 Jul. 14 at 1:15 PM
$AXSM The share price decline ove the past couple of trading sessions has been disappointing but not concerning. The absence of any substantive news affecting the Company’s commercial products, development pipeline, or competitive position is what is most important to me. We all know that any positive information forthcoming during the August 10 earnings call or any announcement about an EU/ROW deal likely will move the share price up quite quickly.
0 · Reply
Mike826_1999
Mike826_1999 Jul. 14 at 12:38 PM
$AXSM Interesting observation... Axsome presented a scientific poster at the International Psychogeriatric Association 2026 Congress in Leiden, The Netherlands, from July 1 through July 3. Poster: Results of a Survey of Care Partners of People Living with Alzheimer's Disease Agitation. From what I can tell, this is only the second recent ex-U.S. scientific presentation by Axsome. Most of their activity has been in the United States. The poster was not new clinical data . It focused on the real-world burden Alzheimer's disease agitation places on caregivers. I'm waiting to see Axsome announce an ex-U.S. partner for Auvelity. I don't know whether this presentation means anything by itself, but presenting ADA data to a European audience certainly does not hurt. At a minimum, it puts Axsome and the Auvelity story in front of international psychogeriatric specialists and key opinion leaders. Probably just another breadcrumb, but it is one I had not noticed before.
3 · Reply
Uncle_Baby_Billy
Uncle_Baby_Billy Jul. 14 at 11:01 AM
$AXSM
0 · Reply
Vakeshka
Vakeshka Jul. 14 at 9:21 AM
$AXSM about time to drop the AXS12 news :-)
0 · Reply
Vakeshka
Vakeshka Jul. 14 at 12:29 AM
$AXSM an insightful article on Pharma M&A trends - note CNS deal value for the first time surpassed oncology in 2025. I wouldn't be surprised if multiple Big Pharma BD teams have actively engaged Axsome. Imho, we're sitting on a goldmine. "...In a historic shift, CNS/neurology captured $30.7 billion in M&A value in 2025 — surpassing oncology ($23.5 billion) for the first time. This reflects the maturation of neuroscience pipelines and Big Pharma's recognition that CNS represents the next frontier of blockbuster drug development..." https://visionlifesciences.com/insights/pharma-ma-tracker-2026
0 · Reply
Georgejj
Georgejj Jul. 13 at 11:23 PM
$AXSM Expect a HUGE increase in sales of Avelity during August 2026 due to Axsome's presence at this week's AAIC 2026 conference. Good luck and GOD bless,
1 · Reply
Georgejj
Georgejj Jul. 13 at 11:15 PM
$AXSM Axsome Therapeutics has established a strong presence at the Alzheimer’s Association International Conference (AAIC), highlighting clinical data for their CNS pipeline. This follows the FDA approval of Auvelity (formerly AXS-05), a novel non-antipsychotic treatment for agitation associated with Alzheimer’s dementia. Good luck and GOD bless,
0 · Reply
Vakeshka
Vakeshka Jul. 13 at 10:21 PM
$AXSM Mizuho Securities reiterated a Buy rating on Axsome Therapeutics, with a price target of $310.00.
0 · Reply
Georgejj
Georgejj Jul. 13 at 9:56 PM
$AXSM Auvelity Expands Treatment Options for Agitation in Alzheimer’s https://psychiatryonline.org/doi/10.1176/appi.pn.2026.07.7.13 Good luck and GOD bless,
0 · Reply